Avia Pharma and Dr Pfleger have entered into a long-term license agreement for Spasmex (Trospium) and Vagitin (Nystatin). The license for Spasmex covers Sweden and Norway and the license for Vagitin covers all Nordic countries.
Spasmex is a well-known product for over-active bladder and is sold in many European countries. Vagitin is a product for vaginal candidiasis that is also sold in many countries.
“We are very pleased that Dr Pfleger has chosen Avia Pharma to launch these products in the Nordics. Spasmex and Vagitin will strengthen our position within gynecology and urology” says Jacob Calmvik, CEO of Avia Pharma